Secondary immunodeficiency is a loss of immune function caused by an outside factor—disease, drug, malnutrition, or organ failure—rather than by an inherited genetic defect. The 10 diseases most often responsible are diabetes, chronic kidney disease, liver cirrhosis, HIV/AIDS, cancer (especially blood cancers), malnutrition, obesity, autoimmune disease, sickle cell disease, and chronic obstructive pulmonary disease. Each disrupts immunity through a measurable mechanism: high blood glucose paralyzes neutrophils, uremia suppresses lymphocytes, and protein loss starves antibody production. Recognizing which disease is dismantling which immune layer changes screening, vaccination timing, and infection monitoring.
How an Acquired Immune Defect Actually Happens
Immunity fails at four checkpoints: barrier integrity, innate cell function, antibody quantity and quality, and T-cell coordination. Secondary immunodeficiency usually strikes one checkpoint hard and the others softly. That is why a person with diabetes gets skin and urinary infections rather than viral pneumonias, while someone on chronic steroids gets both.
The mechanisms are specific and testable. Hyperglycemia above roughly 200 mg/dL impairs neutrophil chemotaxis and phagocytosis within hours. Uremia in advanced kidney disease reduces T-cell proliferation and depletes complement factor D. Cirrhosis shunts portal blood past the liver, so the liver's Kupffer cells stop filtering gut bacteria. Protein-calorie malnutrition drops immunoglobulin synthesis because antibodies are protein structures. These are physical shortages, not vague "weakened immunity."
In plain terms: the immune system is a factory with four assembly lines, and each chronic disease shuts down a different line.
The 10 Diseases, With Their Immune Targets
The table below maps each disease to its primary immune lesion and a representative marker clinicians use to detect it.
| Disease | Primary immune defect | Marker of dysfunction | Most likely infections |
|---|---|---|---|
| Diabetes mellitus | Neutrophil dysfunction; impaired complement | HbA1c >8 percent; glucose >200 mg/dL | Skin, urinary, foot ulcers |
| Chronic kidney disease | T-cell and complement depletion | eGFR <30; BUN >60 mg/dL | Catheter, wound, pneumonia |
| Liver cirrhosis | Kupffer cell failure; opsonin deficit | Child-Pugh C; albumin <2.8 g/dL | Ascites, spontaneous bacteremia |
| HIV/AIDS | CD4 T-cell destruction | CD4 <200 cells/µL | Pneumocystis, TB, fungal |
| Hematologic cancer | Antibody and marrow failure | IgG <400 mg/dL; low neutrophils | Encapsulated bacteria, viral |
| Solid tumors | Local and treatment-related suppression | Neutropenia after chemo | Postsurgical, device-related |
| Protein-energy malnutrition | Antibody and cytokine shortage | Albumin <3.0 g/dL; BMI <18.5 | Respiratory, gut |
| Obesity | Chronic inflammation; T-cell exhaustion | BMI >40; visceral fat | Wound, skin, surgical site |
| Autoimmune disease | Disease and immunosuppressant effect | Low complement; drug counts | Opportunistic, reactivation |
| Sickle cell disease | Splenic infarction; opsonin loss | Nonfunctioning spleen (Howell-Jolly bodies) | Pneumococcus, Salmonella |
The single most important pattern: infections that are frequent, unusual in type, or severe enough to require hospitalization should trigger a search for one of these ten diseases. A doubling of annual infection rate is a stronger signal than a single bad episode.
Diabetes: The Neutrophil Problem Nobody Screens For
Type 1 and type 2 diabetes both raise infection risk, but through glucose, not insulin. When blood glucose exceeds about 200 mg/dL, neutrophils lose their ability to move toward bacteria and engulf them. This effect appears within hours and reverses when glucose normalizes. Per the CDC's 2024 diabetes surveillance data, roughly 38 million Americans have diabetes, and infection-related hospitalization is about 1.5 times higher in this group than in the general population.
The non-obvious detail: the immune defect correlates with glycemic variability more than with average glucose. A person with an A1c of 7.5 percent who swings from 70 to 300 mg/dL has worse neutrophil function at the peaks than someone with a steady 7.8 percent. Continuous glucose monitoring therefore has immunological relevance, not just metabolic relevance.
Practical threshold: an A1c above 8 percent plus two or more infections in a year warrants a formal immunodeficiency workup, including immunoglobulin levels and a vaccine response panel.
Kidney and Liver Disease: Filtration Failure Becomes Immune Failure
Chronic kidney disease causes immunodeficiency in two ways. Uremic toxins directly suppress T-cell proliferation and B-cell antibody production, and the kidney's loss of complement factor D cripples the alternative complement pathway. The result is a measurable defect that appears when eGFR falls below 30 mL/min/1.73 m². Dialysis does not fully correct it. Per 2023 US Renal Data System figures, about 808,000 Americans have kidney failure, and infection is the second leading cause of death in that group after cardiovascular disease.
Cirrhosis works differently. The liver houses Kupffer cells, which clear gut bacteria from portal blood. A failing liver also makes fewer complement proteins and less albumin, the body's main opsonin. Per the 2021 AASLD guidance, about 25 to 30 percent of hospitalized cirrhosis patients develop an infection, and each episode carries an in-hospital mortality near 15 percent. Low albumin below 2.8 g/dL is the strongest single predictor.
In plain terms: kidney failure poisons immune cells, while liver failure removes the filter and the chemical tags that mark bacteria for destruction.
HIV, Cancer, and Malnutrition: The Three Classic Acquired Defects
HIV destroys CD4 T-cells directly. The World Health Organization's 2023 figures put global HIV prevalence at about 39 million people, and immunodeficiency becomes clinically severe when CD4 counts fall below 200 cells/µL. Antiretroviral therapy restores counts in most patients within one to two years, but full immune reconstitution of the mucosal barrier can take longer.
Blood cancers and their treatments are the most potent secondary immunodeficiency triggers in oncology. Multiple myeloma suppresses normal antibody production, so IgG often falls below 400 mg/dL. Chemotherapy-induced neutropenia below 500 cells/µL raises the risk of bacterial sepsis sharply.
Protein-energy malnutrition is the most underdiagnosed cause worldwide. Antibodies are proteins; when dietary protein and calories fall, immunoglobulin synthesis falls with them. Per WHO's 2024 malnutrition estimates, about 148 million children under five are stunted, and infection risk rises at a BMI below 18.5 or an albumin below 3.0 g/dL. This defect corrects fastest of all ten when nutrition is restored.
Obesity, Autoimmune Disease, and Sickle Cell: The Overlooked Three
Obesity was long treated as a metabolic disease with immune side effects. It is better understood as a chronic inflammatory state with real immunodeficiency. Visceral fat secretes inflammatory cytokines that exhaust T-cells and impair wound healing. Data from surgical registries published in 2022 indicate that patients with a BMI above 40 have roughly double the surgical-site infection rate of normal-weight patients, holding procedure type constant.
Autoimmune disease creates immunodeficiency indirectly. The disease itself consumes complement and skews immune signaling, but the dominant cause is treatment. Corticosteroids above 20 mg per day of prednisone equivalent, or biologic agents that block TNF or B-cells, measurably reduce vaccine responses and increase reactivation risk. Per 2022 rheumatology society guidance, patients on these drugs should be screened for hepatitis B and tuberculosis before starting therapy.
Sickle cell disease removes the spleen's filtering function through repeated infarction. By adulthood, most patients have a nonfunctioning spleen, and pneumococcal sepsis risk climbs accordingly. This is why penicillin prophylaxis and pneumococcal vaccination are lifelong standards in this group.
A Timeline of Acquired Immune Decline
The time course matters for screening. Below is the typical order in which defects appear after each trigger begins.
| Trigger | Early change (weeks) | Intermediate (months) | Late (years) |
|---|---|---|---|
| Diabetes | Neutrophil sluggishness at high glucose | Recurrent skin and urinary infections | Chronic foot ulcers, deep infections |
| CKD | Mild T-cell suppression | Complement factor D depletion | Infection-driven mortality risk |
| Cirrhosis | Gut bacterial translocation | Low albumin, weak opsonization | Ascites infection, bacteremia |
| HIV | CD4 decline detectable | CD4 <350; early opportunistic risk | CD4 <200; AIDS-defining infections |
| Malnutrition | Falling immunoglobulin synthesis | Measurable antibody deficit | Wasting, respiratory infections |
| Sickle cell | Splenic function loss begins in childhood | Nonfunctioning spleen by adolescence | Encapsulated bacterial sepsis risk |
Notice that the fastest-moving defect is malnutrition and the slowest is sickle cell splenic loss, which unfolds over years. Screening timing should follow the disease's own clock, not a fixed annual schedule.
What the Numbers Show: Quantified Infection Risk
The magnitude of secondary immunodeficiency varies by disease. Diabetes roughly doubles infection-related hospitalization. Advanced kidney disease raises infection mortality about threefold. Cirrhosis infection carries about 15 percent in-hospital mortality per episode. HIV without treatment progresses to AIDS-defining illness in a median of about 10 years. These are not equivalent risks, and treating them as one category is a common error.
The non-obvious comparison: obesity raises surgical-site infection risk far more than it raises bloodstream infection risk, while kidney disease does the reverse. Matching surveillance to the disease's specific defect is more useful than a generic "immunocompromised" label.
Common Misconceptions and Edge Cases
A frequent misconception is that secondary immunodeficiency requires a low white blood cell count. It does not. Many of these diseases suppress function while cell counts stay normal; diabetes and cirrhosis are the clearest examples.
Another error is assuming vaccination alone solves the problem. Vaccine responses are blunted precisely in the populations that need protection most. Per 2023 transplant and oncology society guidance, live vaccines are contraindicated in many of these patients, and inactivated vaccine timing should be planned around treatment cycles.
The edge case worth flagging: two of these diseases frequently coexist. Diabetes plus kidney disease, or cirrhosis plus malnutrition, produces a compounded defect that is worse than either alone. Screening should account for overlap rather than treating each condition in isolation.
Warning Signs That Need Prompt Evaluation
These red flags warrant medical assessment rather than watchful waiting:
- Two or more severe infections in one year, especially ones requiring hospitalization.
- Infections caused by unusual organisms, such as fungi or atypical bacteria.
- A single infection that fails to respond to standard antibiotics within 72 hours.
- Recurrent infections at the same site, suggesting a structural or immune defect.
- New infection after starting a drug that suppresses immunity.
- Weight loss above 10 percent of body weight in six months with recurrent infections.
What to Actually Do
Concrete actions differ by disease, but the pattern is consistent. First, quantify the defect with a lab panel: immunoglobulin levels, a vaccine response check, and where relevant, CD4 count or neutrophil function. Second, time vaccinations around treatment, not during acute illness. Third, screen for overlapping diseases, since diabetes and kidney disease often coexist. Fourth, track infections in a simple log, because frequency and severity are more informative than any single test.
For clinicians, the practical rule is to treat a rising infection frequency as a diagnostic trigger, not background noise. For patients, the rule is to ask which specific immune layer is at risk, because that determines which infections to watch for and which vaccines to prioritize.
Limits of the Evidence
Not every immune change in these diseases has a proven clinical consequence. Some laboratory abnormalities, such as mildly low immunoglobulin levels in obesity, have uncertain significance. The mechanistic links described here are established for diabetes, kidney disease, cirrhosis, HIV, and malnutrition. For obesity and some autoimmune conditions, the evidence is strong but still evolving, and causal direction is not always clear. Distinguishing confirmed mechanism from plausible association prevents overdiagnosis and unnecessary treatment.